Kiniksa Pharmaceuticals International, plc KNSA
Set alert
As of Nov 2, 3:02 PM ET
- YTD
- +122.70%
- 1 year
- +148.21%
- Open
- 93.10
- Prev close
- 92.24
- Mkt cap
- 7.23B
- Vol
- 701.69K
- Avg vol
- 625.02K
- EPS
- 1.32
- P/E
- 69.68
- Div yield
- 0.00%
More statistics
- Low
- 90.64
- High
- 94.14
- Forward P/E
- 42.80
- Beta
- 0.04
- Short ratio
- 6.53
- Inst. own
- 101.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 78.88
- 200-d avg
- 59.94
- 1y target
- 103.63
5D chart
Events in this range
- Oct 27, 2026Earnings: 0.56; estimate 0.371; surprise 50.94%
- Oct 28, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 28, 2026Rating: Wedbush · Outperform → Outperform
- Oct 28, 2026Rating: Goldman Sachs · Buy → Buy
Signals (136)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 1:40 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 1:40 PM | 1 hour ago |
| MACD: Sell Signal | Nov 2, 1:40 PM | 1 hour ago |
| SMA: Bullish | Nov 2, 1:05 PM | 1 hour ago |
| SMA: Bullish | Nov 2, 1:05 PM | 1 hour ago |
| SMA: Bearish | Nov 2, 1:00 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 1:00 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 12:45 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 12:45 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 12:40 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 12:40 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 12:20 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 12:20 PM | 2 hours ago |
| SMA: Bullish | Nov 2, 12:00 PM | 3 hours ago |
| SMA: Bullish | Nov 2, 11:35 AM | 3 hours ago |
| MACD: Buy Signal | Nov 2, 11:35 AM | 3 hours ago |
| SMA: Bearish | Nov 2, 11:30 AM | 3 hours ago |
| SMA: Bullish | Nov 2, 11:20 AM | 3 hours ago |
| MACD: Sell Signal | Nov 2, 10:10 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 10:05 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 10:05 AM | 4 hours ago |
| MACD: Buy Signal | Nov 2, 9:55 AM | 5 hours ago |
| SMA: Bullish | Nov 2, 9:50 AM | 5 hours ago |
| SMA: Bullish | Nov 2, 9:50 AM | 5 hours ago |
| SMA: Bearish | Nov 2, 9:40 AM | 5 hours ago |
| SMA: Bearish | Nov 2, 9:35 AM | 5 hours ago |
| MACD: Sell Signal | Nov 2, 9:35 AM | 5 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 5 hours ago |
| SMA: Bullish | Nov 2, 9:30 AM | 5 hours ago |
| MACD: Buy Signal | Nov 2, 9:30 AM | 5 hours ago |
| SMA: Bearish | Oct 30, 3:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:10 PM | 3 days ago |
| RSI: Oversold | Oct 30, 11:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 3:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:10 AM | 4 days ago |
| RSI: Overbought | Oct 29, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:50 PM | 5 days ago |
| RSI: Overbought | Oct 28, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 5 days ago |
| RSI: Overbought | Oct 28, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:50 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 6 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 6 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 1:35 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 6 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 6 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 6 days ago |
News
-
2 days ago benzinga.com
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.
-
5 days ago benzinga.com
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $90 to $101.
-
5 days ago benzinga.com
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $99 to $102.
-
5 days ago benzinga.com
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110
Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.
6 days ago fool.com
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.
6 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
6 days ago benzinga.com
Crude Oil Moves Lower; Corning Earnings Top Views
U.S. stocks mostly rose Tuesday: S&P 500 +0.5%, Nasdaq +1.1%, while Dow slipped. Oil fell 1.5%; Corning beat Q3 estimates.
6 days ago marketbeat.com
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to…
6 days ago seekingalpha.com
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
6 days ago benzinga.com
Pentair, JetBlue Airways, Hawkins And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed as Dow slips 0.1%; Pentair jumps 9.8% on strong Q3 results and raised FY26 sales guidance, with several stocks rallying.
6 days ago zacks.com
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per…
6 days ago benzinga.com
Kiniksa Pharmaceuticals Q3 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
6 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
-
6 days ago benzinga.com
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $980.000M-$995.000M to $1.045B-$1.050B vs $996.102M Est
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $980.000 million-$995.000 million to $1.045 billion-$1.050 billion vs $996.102 million estimate.
-
6 days ago benzinga.com
Kiniksa Pharmaceuticals Q3 EPS $0.56 Beats $0.37 Estimate, Sales $285.970M Beat $260.611M Estimate
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.37 by 51.35 percent. This is a 143.48 percent increase over…
6 days ago globenewswire.com
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion –…
1 week ago globenewswire.com
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026…
1 week ago defenseworld.net
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High – Still a Buy?
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday. The company traded as high as $83.78 and last traded…
2 weeks ago defenseworld.net
10,232 Shares of Kiniksa Pharmaceuticals International, plc $KNSA Acquired by B. Riley Wealth Advisors Inc.
B. Riley Wealth Advisors Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) during the third quarter, according to the company in its most recent Form…
2 weeks ago defenseworld.net
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)
Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ: KNSA - Get Free Report) are both mid-cap healthcare companies, but which is the superior…
1 month ago defenseworld.net
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Consensus Price Target of $87.38 According to Brokerages
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company,…
1 month ago zacks.com
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
1 month ago globenewswire.com
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual…
2 months ago marketbeat.com
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
Kiniksa Pharmaceuticals International NASDAQ: KNSA said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of…
2 months ago globenewswire.com
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th…
3 months ago zacks.com
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
-
3 months ago benzinga.com
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.
3 months ago zacks.com
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
-
3 months ago benzinga.com
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $72 to $107.
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98
Canaccord Genuity analyst Edward Nash maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $64 to $98.
-
3 months ago benzinga.com
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $72 to $99.
-
3 months ago benzinga.com
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $100.
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out…
3 months ago benzinga.com
Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results
US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Pharma, OPKO Health, Itron, up over 20%.
3 months ago seekingalpha.com
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
3 months ago benzinga.com
Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting better-than-expected earnings and raising FY26 guidance.
3 months ago marketbeat.com
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
Kiniksa Pharmaceuticals International NASDAQ: KNSA reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the…
3 months ago zacks.com
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.23 per share a year…
-
3 months ago benzinga.com
Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 percent. This is a 30.43 percent increase over…
-
3 months ago benzinga.com
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $930.000 million-$945.000 million to $980.000 million-$995.000 million vs $940.106 million estimate.
3 months ago globenewswire.com
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
- ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243. 6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million --…
-
3 months ago benzinga.com
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.
-
3 months ago benzinga.com
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $74
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $57 to $74.
-
4 months ago benzinga.com
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $72
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $59 to $72.
-
6 months ago benzinga.com
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $60
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $50 to $60.
-
6 months ago benzinga.com
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $59
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $58 to $59.
-
6 months ago benzinga.com
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $57
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $53 to $57.
-
6 months ago benzinga.com
Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $71
Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $58 to $71.
6 months ago benzinga.com
CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.
-
6 months ago benzinga.com
Kiniksa Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Kiniksa Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript